Profusa (PFSA) Stock Soars 173% on $30M PanOmics Diagnostics Acquisition
In a remarkable turn of events, shares of Profusa, a micro-cap biotech firm, skyrocketed by over 173% on Monday, driven by the company's announcement of a $30 million all-stock deal to acquire the PanOmics multi-omics diagnostics platform from BioInsights LLC. Despite this impressive surge, the stock still languishes approximately 99.92% below its value from a year ago, with the company's market capitalization standing at a modest $870,000. The agreement, which was initially signed on March 31, 2026, and subsequently amended on April 3 and 4, grants Profusa exclusive rights to PanOmics' intellectual property and diagnostic technology, specializing in next-generation sequencing applications for cancer diagnostics.
As part of the deal, BioInsights will receive a 3% royalty on net revenues, as well as the right to nominate an independent director for shareholder consideration. Additionally, BioInsights has agreed to provide clinical sample access to support platform validation efforts. The acquisition is contingent upon shareholder approval, successful due diligence, and regulatory clearance. To support the validation of PanOmics and the acquisition of necessary equipment, Profusa intends to raise an additional $10 million through equity financing.
The timing of the acquisition is notable, as it coincides with recent developments in CMS reimbursement policies that favor NGS-based oncology diagnostics. Profusa believes this creates a favorable market environment for the company to expand its revenue streams while its primary LumeeOxygen technology undergoes clinical validation. According to CEO Dr. Ben Hwang, the transaction brings $30 million in stockholder equity value to the company, establishing a foothold in precision diagnostics.
As part of the deal, company leadership will receive new equity compensation representing 12% of fully diluted outstanding shares, aligning management interests with the broadened platform strategy. The transaction involves the issuance of both common stock and non-voting preferred stock, with BioInsights' equity position subject to a seven-year lock-up restriction on the majority of shares received.
Separately, Profusa is collaborating with the Mayo Clinic to deploy its Lumee oxygen monitoring platform for surgical monitoring during pancreatic procedures. With over 13,000 pancreatic resection surgeries conducted annually in the US, the company estimates a $26 million yearly revenue potential for this application. In terms of capital raising, Profusa has modified its securities purchase agreement to authorize the issuance of up to $12.2 million in additional senior secured convertible notes. The company has also issued a note to Ascent Partners Fund, accompanied by a warrant covering 1,111,111 common shares.
Profusa has revised its full-year 2026 revenue guidance upward to a range of $1.5 million–$3 million, driven by expanded purchase orders from European distribution partners for the Lumee monitoring system. This improved outlook comes after the company abandoned plans for a $15 million public offering and discontinued its Bitcoin treasury reserve initiative, selling all its cryptocurrency holdings.